A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss

Obstetrics and Gynecology

Volumn 94, Issue 3, 1999, Pages 330-336

  Weiss, S R ^a   Ellman, H ^b   Dolker, M ^b  

^a S Diego Endocr and Medical Clinic   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESTRADIOL; FOLLITROPIN; PLACEBO; THYROTROPIN;

ADULT; ARTICLE; BONE ATROPHY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FEMALE; HUMAN; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032791280     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(99)00313-0     Document Type: Article

References (26)

1. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 338:1998;736-745.
2. Greenspan S.L., Maitland L.A., Myers E.R., Krasnow M.B., Kido T.H. Femoral bone loss progresses with age A longitudinal study in women over age 65 . J Bone Miner Res. 9:1994;1959-1965.
3. Raisz L.G., Priestwood K.M. Estrogen and the risk of fracture - new data, new questions. N Engl J Med. 334:1998;767-768.
4. Riggs B.L., Melton L.J. III, O'Fallon W.M. Drug therapy for vertebral fractures in osteoporosis Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy . Bone. 18:(suppl):1996;197S-201S.
5. Garnero P., Sornay-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 11:1996;337-349.
6. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
7. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 87:1996;6-12.
8. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
9. Michaelsson K., Baron J.A., Farahmand B.Y., Johnell O., Magnusson C., Persson P.-G., et al. Hormone replacement therapy and risk of hip fracture Population based case-control study . BMJ. 316:1998;1858-1863.
10. Horsman A., Jones M., Francis R., Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 309:1983;1405-1407.
11. Lindsay R., Hart D.M., Clark D.M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 63:1984;759-763.
12. Sharp C.A., Evans S.F., Risteli L., Risteli J., Worsfold M., Davie M.J.W. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women. Eur J Clin Invest. 26:1996;763-771.
13. Genant H.K., Lucas J., Weiss S., Akin M., Emkey R., McNaney-Flint H., et al. Low-dose esterified estrogen therapy Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels . Arch Intern Med. 157:1997;2609-2615.
14. Gordon S.F., Thompson K.A., Ruoff G.E., Imig J.R., Lane P.J., Schwenker C.E., et al. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system Comparison with conjugated estrogens and placebo . Int J Fertil. 40:1995;126-134.
15. Garnero P., Grimaux M., Demiaux B., Preaudat C., Sequin P., Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 7:1992;1389-1398.
16. Pratt D.A., Daniloff Y., Duncan A., Robins S.P. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem. 207:1992;168-175.
17. Robins S.P., Black D., Paterson C.R., Reid D.M., Duncan A., Seibel M.J. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest. 21:1991;310-315.
18. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 75:1988;800-802.
19. Field C.S., Ory S.J., Wahner H.W., Herrmann R.R., Judd H.L., Riggs B.L. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause A two-year placebo-controlled trial . Am J Obstet Gynecol. 168:1993;114-121.
20. Ettinger B. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis. Clin Ther. 15:1993;950-962.
21. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
22. Effects of hormone therapy on bone mineral density Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial . JAMA. 276:1996;1389-1396.
23. Schairer C., Adami H.-O., Hoover R., Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 8:1997;59-65.
24. Kiel D.P., Felson D.T., Anderson J.J., Wilson P.W.F., Moskowitz M.A. Hip fracture and the use of estrogens in postmenopausal women The Framingham Study . N Engl J Med. 317:1987;1169-1174.
25. Griffing G.T., Allen S.H. Estrogen replacement therapy at menopause. How benefits outweigh risks. Postgrad Med. 96:1994;131-140.
26. Belchetz P.E. Hormonal treatment of postmenopausal women. N Engl J Med. 330:1994;1062-1071.